The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...

Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The Medicines and Healthcare Products Regulatory Agency (MHRA) has ruled that warnings about the risk should now be added to ...

With no regionally commissioned services for adult ADHD in Northern Ireland. health trusts have no requirement to manage ...

In a Senate hearing, Robert F. Kennedy, Jr. said that efforts to address the high rates of chronic disease need to start with ...

Adderall shortages have prompted doctors to switch kids with attention-deficit/hyperactivity disorder to other forms of ...

7.“A few months after getting H1N1 flu, I started sleeping for very long periods of time (up to 20 hours, sometimes two days ...

Many with ADHD report that medication — typically a stimulant but treatment can also include non-stimulants and ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.